INFORMATIONAL USE ONLY

Unlabeled Use for Anti-Cancer Drugs - MEDICARE

If you are using an anti-cancer drug off-label please be aware that Medicare covers the off label use only if certain criteria are met. Please use this as a guide to determine if the off label use meets Medicare coverage criteria.

The use is supported by:

PREFERRED SUPPORT (check one or more if applicable)

☐ American Hospital Formulary Service Drug Information
☐ National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium™
☐ Thomson Micromedex DrugDex Compendium
☐ Elsevier Gold Standard’s Clinical Pharmacology compendium

IF PREFERRED SUPPORT NOT APPLICABLE, SEE THE FOLLOWING:

☐ Clinical Research that Appears in Peer-Reviewed Medical Literature (Check any that apply)

☐ American Journal of Medicine
☐ Annals of Internal Medicine
☐ Annals of Oncology
☐ Annals of Surgical Oncology
☐ Biology of Blood and Marrow Transplantation
☐ Bone Marrow Transplantation
☐ Blood
☐ British Journal of Cancer
☐ British Journal of Hematology
☐ British Medical Journal
☐ British Journal of Hematology
☐ Clinical Cancer Research
☐ European Journal of Cancer
☐ Gynecologic Oncology
☐ International Journal of Radiation Oncology * Biology * Physics
☐ Journal of Clinical Oncology
☐ Journal of the American Medical Association
☐ Journal of the National Cancer Institute
☐ Journal of the National Comprehensive Cancer Network
☐ Journal of Urology
☐ Lancet
☐ Lancet Oncology
☐ Leukemia
☐ Radiation Oncology

In the event of an internal or external audit you should be prepared to provide supporting documentation upon request. Auditors for government and commercial health plans will require documentation to support their payment for the drugs.

Version Date: March 23, 2010